Effective therapeutic strategies for protecting the ischemic myocardium are much sought after. Ischemic heart disease in humans is a complex disorder often associated with other systemic diseases such as dyslipidemia, hypertension and diabetes mellitus exerting multiple biochemical effects on the myocardium. Ischemic preconditioning of myocardium is a well-described adaptive response where brief exposure to ischemia markedly enhances the ability of the heart to tolerate a subsequent ischemic episode. The underlying cellular and molecular mechanisms of preconditioning have been extensively investigated in the hope of identifying new therapeutic approaches for the protection of the ischemic myocardium. However, most studies have been undertaken in animal models where ischemia was applied in the absence of other diseases, therefore the clinical relevance is questionable. In this article, we review different ways how systemic disease could modify preconditioning response and we also emphasise the importance of further pre-clinical studies for the specific examination of preconditioning in the presence of other complicating disease.
|Number of pages||8|
|Journal||Lege Artis Medicinae|
|Publication status||Published - Oct 24 2000|
ASJC Scopus subject areas